How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact
Randomized controlled trials reported that pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine rarely selects for drug resistance. However, drug resistance due to PrEP is not completely understood. In daily practice, PrEP will not be used under the well-controlled conditions available i...
Gespeichert in:
| Veröffentlicht in: | PloS one 2016-07, Vol.11 (7), p.e0158620-e0158620 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0158620 |
|---|---|
| container_issue | 7 |
| container_start_page | e0158620 |
| container_title | PloS one |
| container_volume | 11 |
| creator | Dimitrov, Dobromir T Boily, Marie-Claude Hallett, Timothy B Albert, Jan Boucher, Charles Mellors, John W Pillay, Deenan van de Vijver, David A M C |
| description | Randomized controlled trials reported that pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine rarely selects for drug resistance. However, drug resistance due to PrEP is not completely understood. In daily practice, PrEP will not be used under the well-controlled conditions available in the trials, suggesting that widespread use of PrEP can result in increased drug resistance.
We surveyed expert virologists with questions about biological assumptions regarding drug resistance due to PrEP use. The influence of these assumptions on the prevalence of drug resistance and the fraction of HIV transmitted resistance was studied with a mathematical model. For comparability, 50% PrEP-coverage of and 90% per-act efficacy of PrEP in preventing HIV acquisition are assumed in all simulations.
Virologists disagreed on the following: the time until resistance emergence (range: 20-180 days) in infected PrEP users with breakthrough HIV infections; the efficacy of PrEP against drug-resistant HIV (25%-90%); and the likelihood of resistance acquisition upon transmission (10%-75%). These differences translate into projections of 0.6%- 1% and 3.5%-6% infected individuals with detectable resistance 10 years after introducing PrEP, assuming 100% and 50% adherence, respectively. The rate of resistance emergence following breakthrough HIV infection and the rate of resistance reversion after PrEP use is discontinued, were the factors identified as most influential on the expected resistance associated with PrEP. Importantly, 17-23% infected individuals could virologically fail treatment as a result of past PrEP use or transmitted resistance to PrEP with moderate adherence.
There is no broad consensus on quantification of key biological processes that underpin the emergence of PrEP-associated drug resistance. Despite this, the contribution of PrEP use to the prevalence of the detectable drug resistance is expected to be small. However, individuals who become infected despite the use of PrEP should be closely monitored due to higher risk of virological failure when initiating antiretroviral treatment in the future. |
| doi_str_mv | 10.1371/journal.pone.0158620 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1802586267</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A457357738</galeid><doaj_id>oai_doaj_org_article_6709c7e343b44b8f8fa1b76777866359</doaj_id><sourcerecordid>A457357738</sourcerecordid><originalsourceid>FETCH-LOGICAL-c763t-2e59d25d8a30f1848eeef6bbcb12c60182da2511fa437abcf3c12693e40dd4033</originalsourceid><addsrcrecordid>eNqNk99u0zAUxiMEYmPwBggsIfHnosWOk9i5AVVboRVDqwaDS8txTtqUNA6xzban4JVx2mxq0C6mXMQ5_n3fcY7PCYLnBI8JZeT9Wru2ltW40TWMMYl5EuIHwSFJaTjyS_pwb30QPDFmjXFMeZI8Dg5CRlOC0-gw-DvTl-irUyt0otFPQF9q_y0z7Sw6ad0SnYMpjZW1AnTiAFmNFu10gS4MfEQTn_7abyNdoOlVA601b9BZU9alrpGsczS3Bs3ronLQ6X3QrsDr9RqUhRwtXFaVCs1AVnaF5ptGKvs0eFTIysCz_n0UXHyafj-ejU7PPs-PJ6cjxRJqRyHEaR7GOZcUF4RHHACKJMtURkKVYMLDXIYxIYWMKJOZKqgiYZJSiHCeR5jSo-DlzreptBF9LY0gHIddJRPmifmOyLVci6YtN7K9FlqWYhvQ7VLI1paqApEwnCoGNKJZFGW84IUkGUsYY77cNE6912jnZS6hcdnArQ_98isQMaYp73J_6E_nsg3kCmrbymogG-7U5Uos9R8RpZSHNPYGb3uDVv92YKzYlEZBVckatNv-J08i3wL8PijlGBOGPfrqP_TuwvXUUvralHWh_RFVZyomUcxozBjt0o7voPyTw6ZUvqeL0scHgncDgWcsXNmldMaI-bfz-7NnP4bs6z12tW1GoytnfRebIRjtQNVqY1oobu-DYNGN5E01RDeSoh9JL3uxf5e3opsZpP8AUpoveQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1802586267</pqid></control><display><type>article</type><title>How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>SWEPUB Freely available online</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Dimitrov, Dobromir T ; Boily, Marie-Claude ; Hallett, Timothy B ; Albert, Jan ; Boucher, Charles ; Mellors, John W ; Pillay, Deenan ; van de Vijver, David A M C</creator><creatorcontrib>Dimitrov, Dobromir T ; Boily, Marie-Claude ; Hallett, Timothy B ; Albert, Jan ; Boucher, Charles ; Mellors, John W ; Pillay, Deenan ; van de Vijver, David A M C</creatorcontrib><description>Randomized controlled trials reported that pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine rarely selects for drug resistance. However, drug resistance due to PrEP is not completely understood. In daily practice, PrEP will not be used under the well-controlled conditions available in the trials, suggesting that widespread use of PrEP can result in increased drug resistance.
We surveyed expert virologists with questions about biological assumptions regarding drug resistance due to PrEP use. The influence of these assumptions on the prevalence of drug resistance and the fraction of HIV transmitted resistance was studied with a mathematical model. For comparability, 50% PrEP-coverage of and 90% per-act efficacy of PrEP in preventing HIV acquisition are assumed in all simulations.
Virologists disagreed on the following: the time until resistance emergence (range: 20-180 days) in infected PrEP users with breakthrough HIV infections; the efficacy of PrEP against drug-resistant HIV (25%-90%); and the likelihood of resistance acquisition upon transmission (10%-75%). These differences translate into projections of 0.6%- 1% and 3.5%-6% infected individuals with detectable resistance 10 years after introducing PrEP, assuming 100% and 50% adherence, respectively. The rate of resistance emergence following breakthrough HIV infection and the rate of resistance reversion after PrEP use is discontinued, were the factors identified as most influential on the expected resistance associated with PrEP. Importantly, 17-23% infected individuals could virologically fail treatment as a result of past PrEP use or transmitted resistance to PrEP with moderate adherence.
There is no broad consensus on quantification of key biological processes that underpin the emergence of PrEP-associated drug resistance. Despite this, the contribution of PrEP use to the prevalence of the detectable drug resistance is expected to be small. However, individuals who become infected despite the use of PrEP should be closely monitored due to higher risk of virological failure when initiating antiretroviral treatment in the future.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0158620</identifier><identifier>PMID: 27391094</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Anti-HIV Agents - therapeutic use ; Antiretroviral agents ; Antiretroviral drugs ; Biological activity ; Biology and Life Sciences ; Complications and side effects ; Computer simulation ; Controlled conditions ; Demographic aspects ; Drug resistance ; Drug Resistance, Viral ; Drug therapy ; Emergence ; Emtricitabine ; Health aspects ; HIV ; HIV Infections - drug therapy ; Human immunodeficiency virus ; Humans ; Infections ; Mathematical models ; Medicine and Health Sciences ; Microbial drug resistance ; Models, Theoretical ; Mutation ; Patient outcomes ; Pre-Exposure Prophylaxis ; Prophylaxis ; Public Health ; Randomized Controlled Trials as Topic ; Research and Analysis Methods ; Reversion ; Risk factors ; Surveys ; Tenofovir ; Virology</subject><ispartof>PloS one, 2016-07, Vol.11 (7), p.e0158620-e0158620</ispartof><rights>COPYRIGHT 2016 Public Library of Science</rights><rights>2016 Dimitrov et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2016 Dimitrov et al 2016 Dimitrov et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c763t-2e59d25d8a30f1848eeef6bbcb12c60182da2511fa437abcf3c12693e40dd4033</citedby><cites>FETCH-LOGICAL-c763t-2e59d25d8a30f1848eeef6bbcb12c60182da2511fa437abcf3c12693e40dd4033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938235/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938235/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,550,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79343,79344</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27391094$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:133961492$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Dimitrov, Dobromir T</creatorcontrib><creatorcontrib>Boily, Marie-Claude</creatorcontrib><creatorcontrib>Hallett, Timothy B</creatorcontrib><creatorcontrib>Albert, Jan</creatorcontrib><creatorcontrib>Boucher, Charles</creatorcontrib><creatorcontrib>Mellors, John W</creatorcontrib><creatorcontrib>Pillay, Deenan</creatorcontrib><creatorcontrib>van de Vijver, David A M C</creatorcontrib><title>How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Randomized controlled trials reported that pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine rarely selects for drug resistance. However, drug resistance due to PrEP is not completely understood. In daily practice, PrEP will not be used under the well-controlled conditions available in the trials, suggesting that widespread use of PrEP can result in increased drug resistance.
We surveyed expert virologists with questions about biological assumptions regarding drug resistance due to PrEP use. The influence of these assumptions on the prevalence of drug resistance and the fraction of HIV transmitted resistance was studied with a mathematical model. For comparability, 50% PrEP-coverage of and 90% per-act efficacy of PrEP in preventing HIV acquisition are assumed in all simulations.
Virologists disagreed on the following: the time until resistance emergence (range: 20-180 days) in infected PrEP users with breakthrough HIV infections; the efficacy of PrEP against drug-resistant HIV (25%-90%); and the likelihood of resistance acquisition upon transmission (10%-75%). These differences translate into projections of 0.6%- 1% and 3.5%-6% infected individuals with detectable resistance 10 years after introducing PrEP, assuming 100% and 50% adherence, respectively. The rate of resistance emergence following breakthrough HIV infection and the rate of resistance reversion after PrEP use is discontinued, were the factors identified as most influential on the expected resistance associated with PrEP. Importantly, 17-23% infected individuals could virologically fail treatment as a result of past PrEP use or transmitted resistance to PrEP with moderate adherence.
There is no broad consensus on quantification of key biological processes that underpin the emergence of PrEP-associated drug resistance. Despite this, the contribution of PrEP use to the prevalence of the detectable drug resistance is expected to be small. However, individuals who become infected despite the use of PrEP should be closely monitored due to higher risk of virological failure when initiating antiretroviral treatment in the future.</description><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral drugs</subject><subject>Biological activity</subject><subject>Biology and Life Sciences</subject><subject>Complications and side effects</subject><subject>Computer simulation</subject><subject>Controlled conditions</subject><subject>Demographic aspects</subject><subject>Drug resistance</subject><subject>Drug Resistance, Viral</subject><subject>Drug therapy</subject><subject>Emergence</subject><subject>Emtricitabine</subject><subject>Health aspects</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infections</subject><subject>Mathematical models</subject><subject>Medicine and Health Sciences</subject><subject>Microbial drug resistance</subject><subject>Models, Theoretical</subject><subject>Mutation</subject><subject>Patient outcomes</subject><subject>Pre-Exposure Prophylaxis</subject><subject>Prophylaxis</subject><subject>Public Health</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Research and Analysis Methods</subject><subject>Reversion</subject><subject>Risk factors</subject><subject>Surveys</subject><subject>Tenofovir</subject><subject>Virology</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>D8T</sourceid><sourceid>DOA</sourceid><recordid>eNqNk99u0zAUxiMEYmPwBggsIfHnosWOk9i5AVVboRVDqwaDS8txTtqUNA6xzban4JVx2mxq0C6mXMQ5_n3fcY7PCYLnBI8JZeT9Wru2ltW40TWMMYl5EuIHwSFJaTjyS_pwb30QPDFmjXFMeZI8Dg5CRlOC0-gw-DvTl-irUyt0otFPQF9q_y0z7Sw6ad0SnYMpjZW1AnTiAFmNFu10gS4MfEQTn_7abyNdoOlVA601b9BZU9alrpGsczS3Bs3ronLQ6X3QrsDr9RqUhRwtXFaVCs1AVnaF5ptGKvs0eFTIysCz_n0UXHyafj-ejU7PPs-PJ6cjxRJqRyHEaR7GOZcUF4RHHACKJMtURkKVYMLDXIYxIYWMKJOZKqgiYZJSiHCeR5jSo-DlzreptBF9LY0gHIddJRPmifmOyLVci6YtN7K9FlqWYhvQ7VLI1paqApEwnCoGNKJZFGW84IUkGUsYY77cNE6912jnZS6hcdnArQ_98isQMaYp73J_6E_nsg3kCmrbymogG-7U5Uos9R8RpZSHNPYGb3uDVv92YKzYlEZBVckatNv-J08i3wL8PijlGBOGPfrqP_TuwvXUUvralHWh_RFVZyomUcxozBjt0o7voPyTw6ZUvqeL0scHgncDgWcsXNmldMaI-bfz-7NnP4bs6z12tW1GoytnfRebIRjtQNVqY1oobu-DYNGN5E01RDeSoh9JL3uxf5e3opsZpP8AUpoveQ</recordid><startdate>20160708</startdate><enddate>20160708</enddate><creator>Dimitrov, Dobromir T</creator><creator>Boily, Marie-Claude</creator><creator>Hallett, Timothy B</creator><creator>Albert, Jan</creator><creator>Boucher, Charles</creator><creator>Mellors, John W</creator><creator>Pillay, Deenan</creator><creator>van de Vijver, David A M C</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope><scope>DOA</scope></search><sort><creationdate>20160708</creationdate><title>How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact</title><author>Dimitrov, Dobromir T ; Boily, Marie-Claude ; Hallett, Timothy B ; Albert, Jan ; Boucher, Charles ; Mellors, John W ; Pillay, Deenan ; van de Vijver, David A M C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c763t-2e59d25d8a30f1848eeef6bbcb12c60182da2511fa437abcf3c12693e40dd4033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral drugs</topic><topic>Biological activity</topic><topic>Biology and Life Sciences</topic><topic>Complications and side effects</topic><topic>Computer simulation</topic><topic>Controlled conditions</topic><topic>Demographic aspects</topic><topic>Drug resistance</topic><topic>Drug Resistance, Viral</topic><topic>Drug therapy</topic><topic>Emergence</topic><topic>Emtricitabine</topic><topic>Health aspects</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infections</topic><topic>Mathematical models</topic><topic>Medicine and Health Sciences</topic><topic>Microbial drug resistance</topic><topic>Models, Theoretical</topic><topic>Mutation</topic><topic>Patient outcomes</topic><topic>Pre-Exposure Prophylaxis</topic><topic>Prophylaxis</topic><topic>Public Health</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Research and Analysis Methods</topic><topic>Reversion</topic><topic>Risk factors</topic><topic>Surveys</topic><topic>Tenofovir</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dimitrov, Dobromir T</creatorcontrib><creatorcontrib>Boily, Marie-Claude</creatorcontrib><creatorcontrib>Hallett, Timothy B</creatorcontrib><creatorcontrib>Albert, Jan</creatorcontrib><creatorcontrib>Boucher, Charles</creatorcontrib><creatorcontrib>Mellors, John W</creatorcontrib><creatorcontrib>Pillay, Deenan</creatorcontrib><creatorcontrib>van de Vijver, David A M C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dimitrov, Dobromir T</au><au>Boily, Marie-Claude</au><au>Hallett, Timothy B</au><au>Albert, Jan</au><au>Boucher, Charles</au><au>Mellors, John W</au><au>Pillay, Deenan</au><au>van de Vijver, David A M C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2016-07-08</date><risdate>2016</risdate><volume>11</volume><issue>7</issue><spage>e0158620</spage><epage>e0158620</epage><pages>e0158620-e0158620</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Randomized controlled trials reported that pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine rarely selects for drug resistance. However, drug resistance due to PrEP is not completely understood. In daily practice, PrEP will not be used under the well-controlled conditions available in the trials, suggesting that widespread use of PrEP can result in increased drug resistance.
We surveyed expert virologists with questions about biological assumptions regarding drug resistance due to PrEP use. The influence of these assumptions on the prevalence of drug resistance and the fraction of HIV transmitted resistance was studied with a mathematical model. For comparability, 50% PrEP-coverage of and 90% per-act efficacy of PrEP in preventing HIV acquisition are assumed in all simulations.
Virologists disagreed on the following: the time until resistance emergence (range: 20-180 days) in infected PrEP users with breakthrough HIV infections; the efficacy of PrEP against drug-resistant HIV (25%-90%); and the likelihood of resistance acquisition upon transmission (10%-75%). These differences translate into projections of 0.6%- 1% and 3.5%-6% infected individuals with detectable resistance 10 years after introducing PrEP, assuming 100% and 50% adherence, respectively. The rate of resistance emergence following breakthrough HIV infection and the rate of resistance reversion after PrEP use is discontinued, were the factors identified as most influential on the expected resistance associated with PrEP. Importantly, 17-23% infected individuals could virologically fail treatment as a result of past PrEP use or transmitted resistance to PrEP with moderate adherence.
There is no broad consensus on quantification of key biological processes that underpin the emergence of PrEP-associated drug resistance. Despite this, the contribution of PrEP use to the prevalence of the detectable drug resistance is expected to be small. However, individuals who become infected despite the use of PrEP should be closely monitored due to higher risk of virological failure when initiating antiretroviral treatment in the future.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>27391094</pmid><doi>10.1371/journal.pone.0158620</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2016-07, Vol.11 (7), p.e0158620-e0158620 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1802586267 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; SWEPUB Freely available online; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Anti-HIV Agents - therapeutic use Antiretroviral agents Antiretroviral drugs Biological activity Biology and Life Sciences Complications and side effects Computer simulation Controlled conditions Demographic aspects Drug resistance Drug Resistance, Viral Drug therapy Emergence Emtricitabine Health aspects HIV HIV Infections - drug therapy Human immunodeficiency virus Humans Infections Mathematical models Medicine and Health Sciences Microbial drug resistance Models, Theoretical Mutation Patient outcomes Pre-Exposure Prophylaxis Prophylaxis Public Health Randomized Controlled Trials as Topic Research and Analysis Methods Reversion Risk factors Surveys Tenofovir Virology |
| title | How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T02%3A00%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20Much%20Do%20We%20Know%20about%20Drug%20Resistance%20Due%20to%20PrEP%20Use?%20Analysis%20of%20Experts'%20Opinion%20and%20Its%20Influence%20on%20the%20Projected%20Public%20Health%20Impact&rft.jtitle=PloS%20one&rft.au=Dimitrov,%20Dobromir%20T&rft.date=2016-07-08&rft.volume=11&rft.issue=7&rft.spage=e0158620&rft.epage=e0158620&rft.pages=e0158620-e0158620&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0158620&rft_dat=%3Cgale_plos_%3EA457357738%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1802586267&rft_id=info:pmid/27391094&rft_galeid=A457357738&rft_doaj_id=oai_doaj_org_article_6709c7e343b44b8f8fa1b76777866359&rfr_iscdi=true |